The board of directors of the Sino Biopharmaceutical Limited announced that the Iopromide Injection has received the approval for marketing from the National Medical Products Administration of China as a diagnostic agent for intravascular and intracorporeal imaging. Iopromide is a tri-iodinated, non-ionic, water-soluble X-ray contrast agent with high iodine content and good contrast, which is mostly used for electronic computed tomography (CT) enhancement, arteriography and venography, endoscopic retrograde cholangiopancreatography (ERCP), arthography and other body cavity examinations. Iodopromide is stable, easy to use, with better systemic tolerance than ionic contrast agents, no genotoxicity or tumorigenic risk, and good tolerance to blood vessels, paravascular tissues, subarachnoid space, or mucous membranes of the human body.

Due to its superior water solubility, low osmotic pressure, good tolerance, high safety and low toxic side effects, iodopromide has become a widely used iodine contrast agent with great potential in clinical practice. Accompanied by the in-depth promotion of Universal Health Coverage and the wide application of medical imaging technology, the demand for contrast agents in China is high and the market prospect is broad. In 2022, the scale of China's contrast agents market amounted to over RMB 10 billion.

At present, only one generic of iopromide injection has been approved in China, which has not met the large clinical demand. The approval of Duodian will provide more options for the use of iodine contrast agents in clinical medical imaging in China. In addition to Duodian, the Group also has other approved contrast agent products such as gadoxetic acid disodium (trademark name: Xianai(Xian Ai)) and iodixanol (trademark name: Shabeian (Sha Bei An), as well as a number of other contrast agents under research and development.

With the launch of more contrast agent products, the Group is poised for new developments in the medical imaging field for the benefit of more patients.